Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus

Lupus

Volumn 9, Issue 2, 2000, Pages 132-139

  Al Maini, Mustafa Habib ^a   Mountz, John D ^b   Al Mohri, Huda A ^a   El Ageb, Elnour M ^a   Al Riyami, Bazdawi M ^a   Svenson, Karin L G ^c   Zhou, Tong ^b   Richens, Elizabeth R ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b University of Alabama at Birmingham   (United States)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Apoptosis; sFas (sCD95 APO 1); SLE; SLEDAI; SLTCC ACR

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ALBUMIN; AUTOANTIBODY; COMPLEMENT; CREATININE; FAS ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY CELL; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034023145     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828145     Document Type: Article

References (44)

1. Boumpas DT et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, Neuropsychiatric, cardiovascuular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122(12): 940-950.
2. Boumpas DT et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123(1): 42-53.
3. Mitsiades N et al. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. J Clin Endocrinol Metab 1998; 83(6): 2199-2203.
4. Nagata S. Fas-induced apoptosis, and diseases caused by its abnormality. Genes Cells 1996; 1(10) 873-879.
5. French LE, Tschop J. Constitutive Fas Ligand expression in several non-lymphoid mouse tissues: implication for immune-protection and cell turnover. Behring Inst Mitt 1996; 97: 156-160.
6. Kong L et al. Fas and Fas Ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 1997; 40(1): 87-97.
7. Mastsumura R et al. Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjogren's syndrome. Clin Exp Rheumatol 1998; 16(5): 561-568.
8. Tamura M et al. Role of apoptosis of the thyrocytes in rat model of goiter. A possible involvement of Fas system. Endocrinology 1998; 139(8): 3646-3653.
9. Loweth AC et al. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation. Diabetes 1998; 47(5): 727-732.
10. Giordano C, Richiusa P, Sbriglia MS, Pizzolanti G. The role of Fas/Fas ligand and apoptosis in beta-cell death in animal models: relevance for human IDDM. Diabetes Metab Rev 1998; 14(2): 194-195.
11. Kovacs B, Liossis SN, Dennis GJ, Tsokos GC. Increased expression of functional Fas-Ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1998; 25(4): 213-221.
12. Trauth BC et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
13. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-1756.
14. Ju S et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.
15. Watanabe-Fugunaga R, Branna CI, Itoh M et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274-1279.
16. Kramas SM et al. Human hepatocytes produce an isoform of Fas that inhibits apoptosis. Transplantation 1998; 65: 713-721.
17. Itoh N et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243.
18. Mincheff M et al. Fas and Fas ligand expression on human peripheral blood leukocytes. Vox Sanguinis 1998; 74: 113-121.
19. Cheng J et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
20. Knipping E et al. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995; 18: 1735-1737.
21. Goel N et al. Lack of correlation between serum soluble Fas/ APO-1 levels and autoimmune diseases. Arthritis Rheum 1995; 38: 1738-1743.
22. Tokano Y, Miyake S, Kayakai N et al. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol 1996; 16: 261-265.
23. Jodo S et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107: 89-95.
24. Nozawa K et al. Soluble Fas (APO-1 CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40: 1126-1129.
25. Rose LM, Latchman DS, Isenberg DA. Elevated soluble Fas production in SLE correlates with HLA status not with disease activity. Lupus 1997; 6: 717-722.
26. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
27. Bombardier C et al. Derivation of the SLEDAI. Arthritis Rheum 1992; 35: 630-640.
28. Wulka AE et al. Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis Rheum 1997; 40: 57-61.
29. Gladman DD et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 803-813.
30. STATISTICA for Windows, StatSoft, Inc. Tulsa, OK, 1995
31. Fisher LD, Belle JV. Association and prediction: multiple regression analysis, linear models with multiple predictor variables. Biostatistics: Methodology for The Health Sciences. Wiley and Sons: New York, 1993.
32. Bijl M et al. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus? J Autoimmun 1998; 11: 457-463.
33. Rose LM, Latchman DS, Isenberg DA. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br J Rheumatol 1997; 36: 158-163.
34. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415-1420.
35. Perniok A et al. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998; 7: 113-118.
36. Sakata K et al. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes. Eur J Immunol 1998; 28: 2648-2660.
37. Lorenz HM et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997; 40: 306-317.
38. Singh RR, Hahn BH, Tsao BP, Ebling FM. Evidence for multiple mechanisms of polyclonal T cell activation in murine Lupus. J Clin Invest 1998; 102: 1841-1849.
39. Gonzalez-Cuadrado S et al. Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. Kidney Int 1996; 51(6): 1736-1746.
40. Nogae S et al. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: a possible involvement of Fas. J Am Soc Nephrol 1998; 9(4): 620-631.
41. Schelling JR, Nkemere N, Kopp JB, Cleveland RP. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998; 78(7): 813-824.
42. Lieberthal W, Koh JS, Levine JS. Necrosis and apoptosis in acute renal failure. Sem Neph 1998; 18(5): 505-518.
43. Sano H et al. Plasma soluble Fas and soluble Fas Ligand in chronic glomerulonephritis. Nephron 1998; 80(2): 153-161.
44. Berke G. The CTL's kiss of death. Cell 1995; 81: 9-12.